Pharmaceuticals

Cara Therap

Cara Therap released FY2024 annual earnings on March 11, 2025 (EST), with actual revenue of USD 7.137 M and EPS of USD -46.595

Cara Therap released FY2024 Q4 earnings on March 11 (EST), actual revenue USD 1.455 M, actual EPS USD -5.2057

Cara Therap released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of USD 5.682 M and EPS of USD -41.6908

Cara Therap released FY2024 Q3 earnings on November 14 (EST), with actual revenue of USD 2.556 M and EPS of USD -8.28

Cara Therap released FY2024 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 3.126 M and EPS of USD -33.402

Cara Therap released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 991K, actual EPS USD -13.1672

StockNews.com's investment analyst releases report on Cara Therapeutics stock

Cara Therapeutics announces exploration of strategic options

Cara Therap released FY2024 Q1 earnings on May 13 After-Market (EST), actual revenue USD 2.135 M, actual EPS USD -20.2435

Cara Therap released FY2023 annual earnings on March 4 After-Market (EST), actual revenue USD 20.97 M, actual EPS USD -78.7911

Cara Therap released FY2023 Q4 earnings on March 4 After-Market (EST), actual revenue USD 3.004 M, actual EPS USD -21.5265

Cara Therap released FY2023 9 Months Earnings on November 13 After-Market (EST), with actual revenue of USD 17.96 M and EPS of USD -57.5237

Cara Therap released FY2023 Q3 earnings on November 13 After-Market EST, with actual revenue of USD 4.866 M and EPS of USD -18.7199

Cara Therap released FY2023 semi-annual earnings on August 7 After-Market EST, actual revenue USD 13.1 M, actual EPS USD -38.8073

Cara Therap released FY2023 Q2 earnings on August 7 After-Market (EST), with actual revenue of USD 6.933 M and EPS of USD -20.9848

Cara Therapeutics released FY2023 Q1 earnings on May 15 After-Market EST, actual revenue USD 6.165 M, actual EPS USD -17.8188

Cara Therap released FY2022 Q4 earnings on March 6 After-Market EST, actual revenue USD 3.261 M, actual EPS USD -20.3152

Cara Therapeutics released FY2022 annual earnings on March 6 After-Market (EST), actual revenue USD 41.87 M, actual EPS USD -57.36

Cara Therap released FY2022 Q3 earnings on November 7, 2022 (EST), with actual revenue of USD 10.81 M and EPS of USD -15.5321

Cara Therap released FY2022 9 Months Earnings on November 7, 2022 (EST), with actual revenue of USD 38.61 M and EPS of USD -37.1321

Intelligent Bio Solutions

Anghami

UTime

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Northann

FG MERGER II CORP COM USD0.0001 11/02/2030 (SUBS/RTS)

ESH Acquisition

INFLECTION POINT ACQUISITION CORP V COM USD0.0001 CL A (SUB/RIGHST)

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Datavault AI

礼来

ROCHE HOLDINGS AG

罗氏(ADR)

阿斯利康

诺华制药

诺和诺德公司

中外制药(ADR)

UCB(ADR)

第一三共株式会社(ADR)

大冢制药(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Cara Therap(CARA.US)